The CardioWatch 287-2 is a state-of-the-art wearable device designed to continuously monitor pulse rate with exceptional accuracy. Accurate pulse rate monitoring is essential for a range of health applications, including managing cardiovascular conditions, monitoring patients during exercise, and detecting arrhythmias early. Wearable technology like the CardioWatch 287-2 provides a convenient, non-invasive method for continuous monitoring, significantly improving patient outcomes and supplying valuable data to both patients and healthcare providers.

Continuous pulse rate monitoring offers critical insights into cardiovascular health, enabling timely interventions and better management of chronic conditions. Furthermore, early detection of irregular heart rhythms, such as arrhythmias, can lead to prompt medical evaluation and treatment, potentially preventing severe cardiac events.

To validate the CardioWatch 287-2’s pulse rate algorithm, multiple clinical studies were conducted across different centers and populations, comparing its performance against established reference devices such as 12-lead electrocardiograms (ECGs) and finger-clip pulse oximeters. These studies aimed to evaluate the device’s accuracy, reliability, and consistency across a broad population in both resting and active states. The validation process included participants with diverse demographic backgrounds, varying skin types, and different body mass indices to ensure the device’s robustness in real-world scenarios.
This white paper summarizes the findings from these extensive validation studies.

Study Summaries

Study Centre: Amsterdam UMC, Amsterdam, the Netherlands Study Period: July-December 2020
Publication: https://doi.org/10.1016/j.jelectrocard.2021.06.009
Study Population: 180 cardiology patients at rest
Reference Device: 12-lead ECG
Population Characteristics:
- Age: 60 ± 15 years
- Female: 88 (44%)
- Body Mass Index (BMI): 27.0 ± 5.0 kg/m²
- Skin type: I-VI (Fitzpatrick scale)
Measurement Pairs:
- 7,880 pulses
Results:
- Mean Absolute Error (MAE): 0.76 beats per minute (bpm)
- Root Mean Square Error (RMSE): 1.96 bpm
- Correlation: pearson correlation coefficient (R) = 0.991 (95% confidence interval (CI): 0.988-0.993)
- 95% Limits of Agreement (LoA): -3.89 to 3.77 bpm

Conclusion

The extensive validation studies conducted on the CardioWatch 287-2 pulse rate algorithm demonstrate its high accuracy and reliability across a diverse range of populations and conditions. Consistently low mean absolute error (MAE), low (average) root mean square error (RMSE), and high correlation coefficients indicate a strong agreement with reference devices like 12-lead ECGs and finger-clip pulse oximeters.
The CardioWatch 287-2 has shown impressive performance across various pulse rates, and demographics, maintaining its effectiveness. Moreover, the CardioWatch 287-2 has proven to be reliable across different demographic groups, demonstrating consistent accuracy among both male and female participants and across various skin types. This suggests that the device can be trusted for continuous pulse rate monitoring in diverse clinical and non-clinical environments.
The practical applications of the CardioWatch 287-2 are extensive. In healthcare settings, it can be instrumental in monitoring patients with cardiovascular conditions, providing early warnings of arrhythmias, and assisting in perioperative care. The device’s ease of use and non-invasive nature also make it an ideal choice for remote monitoring during both rest and exercice.
In summary, the validation studies firmly establish the CardioWatch 287-2 as a reliable and accurate tool for pulse rate monitoring. Its consistent performance across a wide range of conditions and populations highlights its potential to improve health outcomes through better monitoring and timely interventions. The CardioWatch 287-2 stands out as a valuable device for both clinical practice and remote patient management, offering continuous, reliable pulse rate assessment.